Oncology Institute Inc (TOI) Q1 2026 Earnings Call Transcript

Why It Matters

The earnings underscore TOI’s ability to scale a value‑based oncology model, positioning it for sustainable profitability and deeper payer partnerships in a fragmented market.

Key Takeaways

• Revenue hit $502.7M, up 27.8% YoY
• First profitable quarter adjusted EBITDA $147k
• Capitated revenue grew 17.2% to $80.5M
• Pharmacy revenue surged 49.6% to $269.2M
• AI-driven SG&A efficiencies target $2M savings 2026

Pulse Analysis

TOI’s 2025 results illustrate how integrated oncology platforms can capture growth by marrying capitation contracts with robust pharmacy operations. The company’s aggressive expansion into delegated capitation—particularly in Florida with Elevance, Humana and CarePlus—delivers a higher per‑member‑per‑month rate, allowing TOI to accelerate revenue while maintaining tight medical loss ratios. This model aligns incentives with payers, mitigating the risk of fee‑for‑service volatility and creating a predictable cash flow stream that investors favor in a market increasingly focused on cost containment.

Pharmacy performance emerged as a key profit driver, with a 49.6% revenue jump and an 84.7% gross‑profit increase year‑over‑year. By consolidating Part D dispensing and leveraging scale in drug purchasing, TOI improved its gross margin by over 130 basis points. The company’s strategy to reduce prescription leakage and boost attachment rates demonstrates how vertical integration can enhance both top‑line growth and margin resilience, especially as the Inflation Reduction Act introduces pricing pressures on high‑cost oncology drugs.

Looking ahead, TOI’s guidance for 2026 reflects confidence in continued capitation growth and operational leverage. AI‑enabled SG&A reductions, projected at $2 million, illustrate a broader industry trend of applying technology to streamline revenue‑cycle and prior‑authorization processes. If the company sustains its network expansion and maintains the hybrid care model, it could set a benchmark for value‑based oncology delivery, attracting additional payer contracts and potentially reshaping reimbursement dynamics across the sector.